Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.521306
Title: Determining the mechanism contributing to sub-clinical inflammation in metabolic disease
Author: Creely, Steven J.
Awarding Body: University of Warwick
Current Institution: University of Warwick
Date of Award: 2009
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Restricted access.
Access from Institution:
Abstract:
This thesis aims to investigate the role of innate immunity and the bacterial endotoxin lipopolysaccharide (LPS) in inflammation in adipose tissue. It attempts to do this by: 1) Describing the presence of Toll-like Receptors (TLR) in adipose tissue and adipocytes and their response to stimulation by LPS. It was demonstrated that both Toll-like receptor 2 and 4 were present in adipose tissue and that the receptors were present in greater amount in subjects with diabetes at a protein level and in subjects with obesity at both a RNA and protein level. It was also shown that these receptors responded to stimulation by LPS and that TLR-2 could be seen to be upregulated. 2) It was further shown that LPS induced production of inflammatory cytokines in cultured whole adipose tissue and adipocytes and caused downregulation of adiponectin in whole adiposes tissue. Blockade of NFκB in adipocytes was shown to regulate the levels of inflammatory cytokines produced and to differentially effect this levels dependent on whether whole adipose tissue or isolated adipocytes were cultured. 3) It was shown that LPS levels are significantly higher in the serum of T2DM subjects than controls and that these levels appeared to correlate with insulin. It was also seen that the LPS could be seen to correlate with inflammatory cytokines. It was also demonstrated that treatment with rosiglitazone significantly reduced both insulin and LPS levels in tandem. 4) It was also shown that LPS is significantly higher in NAFLD subjects, correlated with inflammatory cytokines and can be reduced by the use of Orlistat, an intestinal lipase inhibitor.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.521306  DOI: Not available
Keywords: QP Physiology
Share: